BCLC™ AKG-PQQ-Agaricus bisporus Triad for Mitochondrial Function Support: Formulation Engineering and Evidence in Senescent Hepatocytes

Abstract

Background: Mitochondrial dysfunction is increasingly recognized as a central feature of cellular senescence and age-related functional decline [1,2]. Objective: We evaluated a ratio-defined triad containing alpha-ketoglutarate (AKG), pyrroloquinoline quinone disodium (PQQ), and Agaricus bisporus extract, and we aligned the formulation dataset with published mechanistic and human evidence relevant to mitochondrial support. Methods: We summarized composition windows, post-processing retention, and 48 h senescent-hepatocyte readouts, then compared these data with peer-reviewed studies on mitochondrial biogenesis, redox control, and mushroom-derived ergothioneine bioavailability [3-13]. Results: Across the three embodiments, AKG and PQQ retention remained high after processing (98.6-99.2%), while the comparative formula showed lower retention (92.2-92.8%). In senescent hepatocytes, the comparative formula showed lower membrane potential (52.3-65.2% of embodiment values) and higher mitochondrial reactive oxygen species (2.1-2.5-fold versus embodiments). Public evidence supported the mechanistic plausibility of the triad: PQQ has repeatedly been linked with mitochondrial biogenesis signaling [3-8]; AKG has shown protection against mitochondrial dysfunction and oxidative stress in hepatocyte-based models [9]; and ergothioneine from A. bisporus is bioavailable in humans and is increasingly linked with oxidative-stress resilience [11-13]. Conclusion: The triad shows coherent formulation-performance characteristics and biologically plausible multi-target activity, but dedicated human trials of the specific combined system are still required.